China launches major trial to boost survival for kids with rare cancer
NCT ID NCT02845882
Summary
This study aims to improve survival rates for Chinese children and adolescents newly diagnosed with lymphoblastic lymphoma, a rare and aggressive cancer. Researchers are testing a modified version of a standard chemotherapy regimen, adjusting drug doses and treatment length based on how severe the cancer is. The goal is to see if these changes lead to better long-term outcomes compared to previous treatments used in China.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Children's Medical Center
Shanghai, 200127, China
-
West China Second University Hospital
Chengdu, China
Conditions
Explore the condition pages connected to this study.